argenx to Host Annual General Meeting of Shareholders on May 27, 2025

Argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Breda, the Netherlands, April 11, 2025 - Argenx SE (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies, today announced that its Annual General Meeting of Shareholders (AGM) will be held on May 27, 2025.

The AGM will be held at 2:00 PM CET at the company's headquarters, located at Edisonstraat 1, 4838 NM Breda, the Netherlands. The AGM will be followed by a live webcast, allowing shareholders and the broader community to participate remotely.

At the AGM, shareholders will be asked to vote on the re-election of the company's Board of Directors, as well as the appointment of the company's auditor for the 2025 financial year. The meeting will also provide an opportunity for shareholders to ask questions and engage with the company's leadership team.

"We are pleased to invite our shareholders to join us for our Annual General Meeting," said Tim Van Hauwermeiren, Chief Executive Officer of Argenx. "This is an important opportunity for us to connect with our shareholders and provide an update on our progress. We look forward to sharing our achievements and future plans with them."

Shareholders who wish to attend the AGM in person or participate in the webcast should register by May 20, 2025, at the latest. Further details on the registration process and the AGM agenda will be made available in the coming weeks.

About Argenx

Argenx SE is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company is headquartered in Breda, the Netherlands, with operations in the Netherlands, the United States and Canada. For more information, please visit www.argenx.com.